ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,440,294 shares of the biotechnology company’s stock after acquiring an additional 38,761 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.03% of ADMA Biologics worth $41,851,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Larson Financial Group LLC acquired a new position in shares of ADMA Biologics during the third quarter valued at $31,000. GAMMA Investing LLC grew its position in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares in the last quarter. National Bank of Canada FI acquired a new position in ADMA Biologics during the 3rd quarter valued at about $35,000. Harvest Fund Management Co. Ltd bought a new stake in shares of ADMA Biologics during the 3rd quarter worth about $62,000. Finally, Jones Financial Companies Lllp lifted its stake in shares of ADMA Biologics by 303.4% in the 4th quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 4,312 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Stock Performance

Shares of ADMA opened at $18.43 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm’s 50 day moving average is $16.67 and its 200-day moving average is $17.96. ADMA Biologics, Inc. has a 12-month low of $5.88 and a 12-month high of $23.64. The stock has a market capitalization of $4.36 billion, a P/E ratio of 65.82 and a beta of 0.60.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.